THE SHARE: Change: -0.01 SEK (-4.65%) / Price: 0.18 SEK / May 19, 2025, 1:13 pm (CEST)
  • Home
  • About
    • Introduction
    • Board of Directors
    • Management Team
    • Medical Advisors
    • Corporate Governance
    • Career
  • Technology
    • Physiological Targeting
    • Functional Nanoparticles
    • Publications
    • Patent
  • Portfolio
    • Pipeline
    • SpagoPix
    • Tumorad
  • Investor Relations
    • The Share
    • Analyst Coverage
    • Owners
    • Financial Reports
    • Financial Calendar
    • Equity research
    • Shareholder’s Personal Data
    • Share Issue
  • Media
    • Spago Nanomedical in media
    • Press Releases
    • Subscribe
    • Presentations
    • Events
    • Image Bank
  • Contact
    • Contact us

MAR

  • 22 Sep, 2017
    Kommuniké från bolagsstämma i Spago Nanomedical AB (publ)
  • 25 Aug, 2017
    Spago Nanomedical delårsrapport januari-juni 2017
  • 22 Aug, 2017
    Kallelse till extra bolagsstämma i Spago Nanomedical AB (publ)
  • 22 Aug, 2017
    Styrelsen i Spago Nanomedical AB (publ) beslutar om företrädesemission inför kliniska studier
  • 8 Jun, 2017
    Spago Nanomedical and Charles River Laboratories announce agreement forpreclinical studies of SpagoPix
  • 8 Jun, 2017
    Spago Nanomedical tecknar avtal med Charles River Laboratories för prekliniska studier av SpagoPix
  • 13 Mar, 2017
    Kommentar till att EMA-kommitté vill dra in flera MR-kontrastmedel
  • 17 Feb, 2017
    SpagoPix visar lovande resultat i toxikologiska pilotstudier
  • 17 Feb, 2017
    Promising results in toxicological pilot studies with SpagoPix
  • 14 Feb, 2017
    Spago Nanomedical AB bokslutskommuniké januari – december 2016
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • Previous
  • Next
Back

About Spago Nanomedical

Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of life-threatening and debilitating diseases.

Address

Spago Nanomedical AB
Scheelevägen 22
SE-223 63 Lund
Sweden

Contact

Phone: +46 46 811 88
LinkedIn

Member of:

Copyright © 2025 Spago Nanomedical AB. All Rights Reserved.
Design by Clavis Communications